UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2015
Commission File Number: 001-36582
Auris Medical Holding AG
(Exact name of registrant as specified in its charter)
Bahnhofstrasse 21
6300 Zug, Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):
INCORPORATION BY REFERENCE
Exhibits 99.1 and 99.2 to this report on Form 6-K shall be deemed to be incorporated by reference
into the registration statements on Form F-3 (Registration Number 333-206710) and Form S-8 (Registration Numbers 333-198037 and
333-200805) of Auris Medical Holding AG and to be a part thereof from the date on which this report is filed, to the extent not
superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Auris Medical Holding AG |
|
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Thomas Meyer |
|
|
|
|
|
Name: |
Thomas Meyer |
|
|
|
|
|
Title: |
Chief Executive Officer |
|
Date: November 12, 2015
EXHIBIT INDEX
Exhibit
Number |
Description |
99.1 |
Unaudited Condensed Consolidated Interim Financial Statements |
99.2 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
99.3 |
Press Release dated November 12, 2015 |
Exhibit 99.1
Unaudited Condensed Consolidated Interim Financial Statements as
of September 30, 2015 and December 31, 2014 and for the Three and Nine Months Ended September 30, 2015 and 2014
Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income
(Loss)
Condensed Consolidated Interim Statement of Financial Position
Condensed Consolidated Interim Statement of Changes in Equity
Condensed Consolidated Interim Statement of Cash Flows
Notes to the Condensed Consolidated Interim Financial Statements
Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive
Income (Loss) (unaudited)
For the Three and Nine Months Ended September 30, 2015 and 2014 (in CHF)
|
|
THREE MONTHS ENDED
SEPT. 30 |
|
NINE
MONTHS ENDED SEPT. 30 |
|
|
2015 |
|
2014 |
|
2015 |
|
2014 |
Research and development |
|
-5,884,313 |
|
-4,686,442 |
|
-20,865,100 |
|
-13,036,450 |
General and administrative |
|
-1,326,750 |
|
-997,733 |
|
-3,236,856 |
|
-3,552,021 |
Operating loss |
|
-7,211,063 |
|
-5,684,175 |
|
-24,101,956 |
|
-16,588,471 |
Interest income |
|
12,873 |
|
6,023 |
|
23,141 |
|
35,908 |
Interest expense |
|
-1,608 |
|
-1,245 |
|
-6,212 |
|
-53,877 |
Foreign currency exchange gains/losses, net |
|
1,988,870 |
|
2,318,569 |
|
-136,438 |
|
2,394,429 |
Net loss before tax and attributable to |
|
|
|
|
|
|
|
|
owners of the Company |
|
-5,210,928 |
|
-3,360,828 |
|
-24,221,465 |
|
-14,212,011 |
Other comprehensive income (loss): |
|
|
|
|
|
|
|
|
Items that will never be reclassified to |
|
|
|
|
|
|
|
|
profit or loss |
|
|
|
|
|
|
|
|
Remeasurement of defined benefit liability, |
|
-3,792 |
|
111,550 |
|
-232,962 |
|
-312,261 |
net of taxes of CHF 0.00 |
|
|
|
|
|
|
|
|
Items that are or may be reclassified to |
|
|
|
|
|
|
|
|
profit or loss |
|
|
|
|
|
|
|
|
Foreign currency translation differences, |
|
-40,524 |
|
-74,115 |
|
16,339 |
|
-71,298 |
net of taxes of CHF 0.00 |
|
|
|
|
|
|
|
|
Other comprehensive income (loss), |
|
-44,316 |
|
37,435 |
|
-216,623 |
|
-383,559 |
net of taxes of CHF 0.00 |
|
|
|
|
|
|
|
|
Total comprehensive loss attributable
to owners of the Company |
|
-5,255,244 |
|
-3,323,393 |
|
-24,438,088 |
|
-14,595,570 |
Basic and diluted loss per share |
7 |
-0.15 |
|
-0.14 |
|
-0.76 |
|
-0.69 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes form an integral part of these condensed
consolidated interim financial statements
Condensed Consolidated Interim Statement of Financial Position (unaudited)
As of September 30, 2015 and December 31, 2014 (in CHF)
|
|
|
SEPTEMBER 30,
2015 |
|
DECEMBER 31,
2014 |
|
Note |
|
|
ASSETS |
|
|
|
|
|
Non-current assets |
|
|
|
|
|
Property and equipment |
|
|
247,129 |
|
235,427 |
Intangible assets |
|
|
1,482,520 |
|
1,482,520 |
Deferred tax asset |
|
|
- |
|
32,761 |
Total non-current assets |
|
|
1,729,649 |
|
1,750,708 |
|
|
|
|
|
|
Current assets |
|
|
|
|
|
Other receivables |
|
|
575,954 |
|
542,538 |
Prepayments |
|
|
294,466 |
|
265,170 |
Cash and cash equivalents |
|
|
55,400,708 |
|
56,934,325 |
Total current assets |
|
|
56,271,128 |
|
57,742,033 |
|
|
|
|
|
|
Total assets |
|
|
58,000,777 |
|
59,492,741 |
|
|
|
|
|
|
EQUITY AND LIABILITIES |
|
|
|
|
|
Equity |
|
|
|
|
|
Share capital |
3 |
|
13,717,556 |
|
11,604,156 |
Share premium |
|
|
112,645,019 |
|
93,861,171 |
Foreign currency translation reserve |
|
|
-34,770 |
|
-51,108 |
Accumulated deficit |
|
|
-76,378,540 |
|
-52,131,426 |
Total shareholders’ equity attributable to owners of the Company |
|
|
49,949,265 |
|
53,282,793 |
|
|
|
|
|
|
Non-current liabilities |
|
|
|
|
|
Employee benefits |
|
|
1,758,770 |
|
1,410,598 |
Deferred tax liabilities |
|
|
327,637 |
|
360,398 |
Total non-current liabilities |
|
|
2,086,407 |
|
1,770,996 |
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
Trade and other payables |
|
|
2,822,445 |
|
3,234,384 |
Accrued expenses |
|
|
3,142,660 |
|
1,204,568 |
Total current liabilities |
|
|
5,965,105 |
|
4,438,952 |
|
|
|
|
|
|
Total liabilities |
|
|
8,051,512 |
|
6,209,948 |
|
|
|
|
|
|
Total equity and liabilities |
|
|
58,000,777 |
|
59,492,741 |
The accompanying notes form an integral part of these condensed consolidated interim
financial statements
Condensed Consolidated Interim Statement of Changes in Equity (unaudited)
As of September 30, 2015 and 2014 (in CHF)
ATTRIBUTABLE TO OWNERS OF THE COMPANY |
|
NOTE |
SHARE
CAPITAL |
SHARE
PREMIUM |
FX
TRANSLATION
RESERVE |
ACCUMULATED
DEFICIT |
TOTAL
EQUITY |
Balance at January 1, 2014 |
|
6,487,130 |
35,608,210 |
53,995 |
-33,115,689 |
9,033,646 |
Total comprehensive loss |
|
|
|
|
|
|
Net loss |
|
- |
- |
- |
-14,212,011 |
-14,212,011 |
Other comprehensive income/(-loss) |
|
- |
- |
-71,298 |
-312,261 |
-383,559 |
Total comprehensive loss |
|
- |
- |
-71,298 |
-14,524,272 |
-14,595,570 |
Transactions with owners of the Company |
|
|
|
|
|
|
Capital increase from IPO |
|
4,045,294 |
47,261,446 |
- |
- |
51,306,740 |
Share issuance costs |
|
- |
-682,860 |
- |
- |
-682,860 |
Transaction costs |
|
- |
-1,154,569 |
- |
- |
-1,154,569 |
Conversion of convertible loans |
|
1,043,180 |
12,717,655 |
- |
- |
13,760,835 |
Share based payments |
5 |
- |
- |
- |
238,203 |
238,203 |
Share options exercised |
3 |
6,200 |
43,400 |
- |
- |
49,600 |
Balance at September 30, 2014 |
|
11,581,804 |
93,793,282 |
-17,303 |
-47,401,758 |
57,956,025 |
Balance at January 1, 2015 |
|
11,604,156 |
93,861,171 |
-51,109 |
-52,131,426 |
53,282,792 |
Total comprehensive loss |
|
|
|
|
|
|
Net loss |
|
- |
- |
- |
-24,221,465 |
-24,221,465 |
Other comprehensive income/(-loss) |
|
- |
- |
16,339 |
-232,962 |
-216,623 |
Total comprehensive loss |
|
- |
- |
16,339 |
-24,454,427 |
-24,438,088 |
Transactions with owners of the Company |
|
|
|
|
|
|
Capital increase from follow-on offering |
|
2,110,000 |
19,604,877 |
- |
- |
21,714,877 |
Transaction costs |
|
- |
-643,796 |
- |
- |
-643,796 |
Share issuance costs |
|
- |
-210,826 |
- |
- |
-210,826 |
Share based payments |
5 |
- |
- |
- |
207,313 |
207,313 |
Share options exercised |
3 |
3,400 |
33,593 |
- |
- |
36,993 |
Balance at September 30, 2015 |
|
13,717,556 |
112,645,019 |
-34,770 |
-76,378,540 |
49,949,265 |
The accompanying notes form an integral part of these condensed
consolidated interim financial statements
Condensed Consolidated Interim Statement of Cash Flows (unaudited)
For the Nine Months Ended September 30, 2015 and 2014 (in CHF)
|
Note |
NINE MONTHS ENDED
SEPTEMBER 30, 2015 |
|
NINE MONTHS ENDED
SEPTEMBER 30, 2014 |
|
Cash flows from operating activities |
|
|
|
|
Net loss |
|
-24,221,465 |
|
-14,212,011 |
Adjustments for: |
|
|
|
|
Depreciation |
|
68,217 |
|
53,291 |
Unrealized net foreign currency exchange gain/(loss) |
|
168,232 |
|
-2,462,886 |
Net interest (income)/expense |
|
-22,969 |
|
13,727 |
Share option compensation |
5 |
207,313 |
|
238,202 |
Employee benefits |
|
115,211 |
|
-13,338 |
|
|
|
|
|
Changes in: |
|
|
|
|
Other receivables |
|
-33,428 |
|
-187,147 |
Prepayments |
|
-29,296 |
|
-150,258 |
Trade and other payables |
|
-411,937 |
|
2,658,211 |
Accrued expenses |
|
1,938,089 |
|
-301,141 |
|
|
|
|
|
Changes in net working capital |
|
1,463,428 |
|
2,019,665 |
|
|
|
|
|
Cash used in operating activities |
|
-22,222,033 |
|
-14,363,350 |
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
Purchase of property and equipment |
|
-79,917 |
|
-102,746 |
Interest received |
|
22,969 |
|
35,908 |
Net cash used in investing activities |
|
-56,948 |
|
-66,838 |
|
|
|
|
|
Cash flows from (used in) financing activities |
|
|
|
|
Proceeds from share capital increase |
|
36,993 |
|
49,600 |
Share issuance costs |
|
-210,826 |
|
-682,860 |
Proceeds from IPO, net |
|
- |
|
50,698,334 |
Proceeds from follow-on offering, net |
|
21,071,081 |
|
- |
Net cash from (used in) financing activities |
|
20,897,248 |
|
50,065,074 |
Net increase (decrease) in cash and cash equivalents |
|
-1,381,733 |
|
35,634,886 |
Cash and cash equivalents at beginning of the period |
|
56,934,325 |
|
23,865,842 |
Net effect of currency translation on cash |
|
-151,885 |
|
2,391,932 |
Cash and cash equivalents at end of the period |
|
55,400,707 |
|
61,892,660 |
The accompanying notes form an integral part of these condensed consolidated interim
financial statements
AURIS MEDICAL HOLDING AG
Notes to the Condensed Consolidated Interim Financial Statements
as of September 30, 2015 and December 31, 2014 and for the Three
and Nine Months Ended September 30, 2015 and 2014 (in CHF)
Auris Medical Holding AG (the “Company”) is domiciled
in Switzerland. The Company’s registered address is at Bahnhofstrasse 21, 6300 Zug. These condensed consolidated interim
financial statements comprise the Company and its subsidiaries (together referred to as the “Group” and individually
as “Group entities”). The Company is the ultimate parent of the following Group entities:
| § | Auris Medical AG, Basel, Switzerland (100%) |
| § | Otolanum AG, Zug, Switzerland (100%) |
| § | Auris Medical Inc., Chicago, United States (100%) |
| § | Auris Medical Ltd., Dublin, Ireland (100%) |
The Group is primarily involved in the development of pharmaceutical
products for the treatment of inner ear disorders, in particular tinnitus and hearing loss. Its most advanced projects are in the
late stage of clinical development.
Statement of compliance
These condensed consolidated interim financial statements as of
September 30, 2015 and for the three and nine months ended September 30, 2015 and the condensed consolidated financial statements
as of December 31, 2014 have been prepared in accordance with International Accounting Standard Interim Financial Reporting
(“IAS 34”) and should be read in conjunction with the audited consolidated financial statements as of and for the year
ended December 31, 2014.
These condensed consolidated interim financial statements include
all adjustments, that are necessary to fairly state the results of the interim period and the Group believes that the disclosures
are adequate to make the information presented not misleading. Interim results are not necessarily indicative of results to be
expected for the full year. Management does not consider the business to be seasonal or cyclical.
Certain information and footnote disclosures normally included in
financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by
the International Accounting Standards Board, have been condensed or omitted as permitted by IAS 34. The condensed consolidated
statement of financial position as of December 31, 2014 was derived from the audited consolidated financial statements.
The interim financial statements were authorized for issuance by
the Company’s Audit Committee on November 9, 2015.
Functional and reporting currency
These condensed consolidated financial statements are presented
in Swiss Francs (“CHF”), which is the Company’s functional currency (“functional currency”) and the
Group’s reporting currency.
Segment reporting
A segment is a distinguishable component of the Group that engages
in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions
with any of the Group’s other components. Management has determined that there is only one operating segment under the requirements
of IFRS 8 (“Operating Segments”).
Significant accounting policies
The accounting policies applied by the Group in these condensed
consolidated interim financial statements are the same as those applied by the Group in its audited consolidated financial statements
as of and for the year ended December 31, 2014 and have been applied consistently to all periods presented in these condensed consolidated
interim financial statements, unless otherwise indicated.
New standards, amendments and interpretations adopted by the
Group
The Group has not early adopted any standard, interpretation or
amendment that was issued, but is not yet effective.
A number of new standards, amendments to standards and interpretations
are effective for the Group’s 2015 reporting year, and have not been applied in preparing these condensed consolidated interim
financial statements. Management does not believe that the adoption of these standards, interpretations, or amendments will have
a material impact on the financial statements of the Group.
Share capital
The issued share capital of the Company consisted of:
|
Common Shares
(Number) |
|
Preferred Shares
(Number) |
|
2015 |
2014 |
|
2015 |
2014 |
As of January 1 |
29,010,391 |
72,600 |
|
— |
16,145,225 |
Common shares issued for stock option exercises with a nominal value of CHF 0.40 each |
8,500 |
15,500 |
|
— |
— |
Preferred shares “C” issued for conversion of convertible loan with a nominal value of CHF 0.40 each |
— |
— |
|
— |
2,607,950 |
Common shares issued for the IPO with a nominal value of CHF 0.40 each |
— |
10,113,235 |
|
— |
— |
Common shares resulting from conversion of Preferred Shares at the time of the IPO with a nominal value of CHF 0.40 each |
— |
18,753,175 |
|
— |
-18,753,175 |
Common shares issued for the follow-on offering with a nominal value of CHF 0.40 each |
5,275,000 |
— |
|
— |
— |
Total, as of September 30 |
34,293,891 |
28,954,510 |
|
— |
— |
All shares have a nominal value of CHF 0.40 and are fully paid in. As of September
30, 2015, the nominal value of the 34,293,891 issued shares amounted to CHF 13,717,556 (as of December 31, 2014, the nominal
value of 29,010,391 issued shares amounted to CHF 11,604,156).
Issue of common shares upon exercise of options
During the nine months ended September 30, 2014, three beneficiaries
of the Option Plan A exercised their right to acquire common shares of the Company at CHF 3.20 per share. This resulted in an increase
in the number of outstanding common shares of 15,500 and an increase in the share capital of CHF 6,200. Total proceeds from the
exercise to the Company were CHF 49,600.
During the nine months ended September 30, 2015, beneficiaries of
the Option Plan A exercised their right to acquire common shares of the Company at CHF 3.20 per share. This resulted in an increase
in the number of outstanding common shares of 8,500 and an increase in the share capital of CHF 3,400. Total proceeds from the
exercise to the Company were CHF 27,200. The Company also recorded the difference of CHF 9,793 between the exercise price and market
price at the day of exercise in the share premium.
Follow-On Offering on NASDAQ Global Market
On May 20, 2015, the Company completed a public offering of 5,275,000
shares, yielding net proceeds after underwriting discounts of USD 23.6 million (CHF 21.7 million). Following the offering (and
settlement of the aforementioned employee options) there were 34,293,891 common shares of the Company outstanding.
IPO on NASDAQ Global Market
In August 2014, the Company completed its Initial Public Offering
(“IPO”) issuing 10,113,235 shares, including the underwriter’s overallotment option, yielding total net proceeds
of CHF 51.3 million (USD 56.4 million). Following the IPO there were 28,954,510 common shares of the Company outstanding. At December
31, 2014 there were 29,010,391 shares outstanding following the exercise of options.
Pursuant to agreements with holders of preferred shares, all preferred
shares outstanding at the time of the IPO converted automatically into common shares at the ratio of 1:1 upon consummation of the
IPO.
Issuance of preferred shares
In January 2014, a convertible loan was converted into 2,607,950 preferred shares Series
C with a nominal value of CHF 0.40 at a conversion price of CHF 5.28 each.
|
Nine months ended
September 30, 2015 |
|
Nine months ended
September 30, 2014 |
|
|
Salaries |
1,920,616 |
|
1,542,359 |
|
Pension costs |
239,247 |
|
89,612 |
|
Other social benefits |
141,745 |
|
128,315 |
|
Share based compensation expense |
207,313 |
|
238,202 |
|
Other |
22,692 |
|
59,334 |
|
Total employee benefits |
2,531,613 |
|
2,057,822 |
|
| 5. | Share based compensation expense |
Share based compensation expense of CHF 207,313 was recognized during
the nine month period ended September 30, 2015 (for the nine months ended September 30, 2014: CHF 238,202). A total of 234,750
options were granted in the nine month period ended September 30, 2015. The exercise price of the options granted was the average
closing price in the 30 days preceding the grant date, which was USD 5.98 for 95,750 options granted in March 2015 and USD 4.68
for 139,000 options granted in September 2015. The methodology for computation of share based compensation expense for the period
is consistent with the methodology used in 2014.
|
|
Three months ended
September 30, |
Nine months ended
September 30, |
|
|
2015 |
2014 |
2015 |
2014 |
Loss attributable to owners of the Company |
|
(5,210,928) |
(3,360,828) |
(24,221,465) |
(14,212,011) |
Weighted average number of shares outstanding |
|
34,290,141 |
24,589,852 |
31,828,984 |
20,488,392 |
Basic and diluted loss per share |
|
(0.15) |
(0.14) |
(0.76) |
(0.69) |
For the nine months ended September 30, 2015 and September 30, 2014
basic and diluted loss per share is calculated based on the weighted average number of shares issued and outstanding and excludes
shares to be issued under the stock option plans, as they would be anti-dilutive. As of the date hereof, the Company has 645,260
options outstanding under its stock option plans. The average number of options outstanding between January 1, 2015 and September
30, 2015 was 527,885 (262,500 for the period between January 1, 2014 and September 30, 2014). The average number of options outstanding
between June 30, 2015 and September 30, 2015 was 575,760 (311,250 for the period between June 30, 2014 and September 30, 2014).
Exhibit 99.2
Management’s
Discussion and Analysis of Financial Condition and Results of Operations
This management’s discussion and analysis is designed to provide
you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction
with our unaudited condensed consolidated interim financial statements as of and for the three and nine month periods ended September
30, 2014 and 2015 included as Exhibit 99.1 to this Report on Form 6-K, which have been prepared in accordance with International
Accounting Standard (“IAS”) 34, Interim Financial Reporting. We also recommend that you read our management’s
discussion and analysis and our audited consolidated financial statements and the notes thereto, which appear in our Annual Report
on Form 20-F for the year ended December 31, 2014 (the “Annual Report”) filed with the U.S. Securities and Exchange
Commission (the “SEC”) pursuant to the U.S. Securities and Exchange Act of 1934, as amended.
Unless otherwise indicated or the context otherwise requires, all
references to “Auris Medical” or the “company,” “we,” “our,” “ours,”
“us” or similar terms refer to Auris Medical AG and its subsidiaries prior to the completion of our corporate reorganization
in connection with our initial public offering, and Auris Medical Holding AG and its subsidiaries as of the completion of our corporate
reorganization and thereafter.
We prepare and report our consolidated financial statements and financial
information in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International
Accounting Standards Board (the “IASB”). None of our financial statements were prepared in accordance with generally
accepted accounting principles in the United States. We maintain our books and records in Swiss Francs. We have made rounding adjustments
to some of the figures included in this management’s discussion and analysis. Accordingly, numerical figures shown as totals
in some tables may not be an arithmetic aggregation of the figures that precede them. Unless otherwise indicated, all references
to currency amounts in this discussions and analysis are in Swiss Francs.
This discussion and analysis is dated as of November 12, 2015.
Overview
We are a clinical-stage biopharmaceutical company focused on the
development of novel products for the treatment of inner ear disorders. Our most advanced product candidate, AM-101, is in Phase
3 clinical development for acute inner ear tinnitus under a special protocol assessment, or SPA, from the FDA. In two Phase 2 clinical
trials, AM-101 demonstrated a favorable safety profile and statistically significant improvement in tinnitus loudness and other
patient reported outcomes. We expect to have first top-line Phase 3 clinical data for AM-101 in the second quarter of 2016. We
are also developing AM-111 for acute inner ear hearing loss. We are preparing two pivotal Phase 3 clinical trials in the treatment
of idiopathic sudden sensorineural hearing loss, or ISSNHL, titled HEALOS and ASSENT. We expect to start enrollment in HEALOS in
the fourth quarter of 2015 and in ASSENT in the first half of 2016. In addition, we are preparing a Phase 2 trial titled REACH
in order to test AM-111 in the treatment of cochlear implantation surgery-induced hearing loss. We intend to seek grant funding
for REACH and expect to start enrollment for the trial in the third quarter of 2016. Both acute inner ear tinnitus and hearing
loss are conditions for which there is high unmet medical need, and we believe that we have the potential to be the first to market
in these indications.
To date, we have financed our operations through public offerings
of our common shares, private placements of equity securities and short term loans. We have no products approved for commercialization
and have never generated any revenues from royalties or product sales. As of September 30, 2015, we had cash and cash equivalents
of CHF 55.4 million. Based on our current plans, we do not expect to generate royalty or product revenues unless and until we obtain
marketing approval for, and commercialize AM-101, AM-111 or any of our other product candidates.
Since inception, we have incurred
significant operating losses. We incurred net losses (defined as net losses attributable to the owners of the Company) of CHF 18.2
million and CHF 15.0 million for the years ended December 31, 2014 and 2013, respectively. As of September 30, 2015, we had an
accumulated deficit of CHF 76.4 million. We expect to continue incurring losses as we continue our clinical and pre-clinical development
programs, apply for marketing approval for our product candidates and, subject to obtaining regulatory approval of our product
candidates, build a sales and marketing force in preparation for the potential commercialization of our product candidates.
On May 20, 2015, we completed a public offering of common shares
pursuant to a Registration Statement on Form F-1, as amended (Registration No. 333-203554). Under the registration statement, we
sold an aggregate of 5,275,000 common shares at a price to the public of US$4.75 per share. The underwriting discounts and offering
expenses totaled US$ 0.7 million. The offering expenses included SEC registration fees, FINRA filing fees, Nasdaq listing fees
and expenses, legal fees and expenses, printing expenses, transfer agent fees and expenses, accounting fees and expenses, as well
as other miscellaneous fees and expenses. In addition to offering expenses, the proceeds of the offering were subject to 1% stamp
duty taxes. The net proceeds of the public offering after underwriting discounts were US$23.6 million (CHF 21.7 million).
On September 1, 2015, we filed a shelf registration statement on
Form F-3 (333-206710) with the SEC to register for one or more offerings of common shares, senior debt securities, subordinated
debt securities, warrants, purchase contracts or units with a maximum aggregate offering price of up to US$ 100 million. The shelf
registration statement was declared effective on September 10, 2015.
There have been no developments in the previously disclosed patent
interference involving our issued patent No. 9,066,865 and Otonomy Inc.’s patent application No. 13/848,636.
Collaboration and License Agreements
There have been no material changes to our collaboration and license
agreements from those reported in “Item 5—Operating and Financial Review and Prospects–Operating results—Collaboration
and License Agreements” in the Annual Report.
Research and Development Expense
Our research and development expense is highly dependent on the development
phases of our research projects and therefore may fluctuate substantially from period to period. Our research and development expense
mainly relates to the following key programs:
| · | AM-101. We are conducting a Phase 3 program comprising two pivotal Phase 3 clinical trials (TACTT2 and TACTT3) as well as two
open label extension studies (AMPACT1 and AMPACT2). We expect first top-line data from the TACTT trials in the second quarter of
2016. We anticipate that our research and development expenses in connection with these clinical trials will be substantially higher
in 2015 than in the previous financial year. |
| · | AM-111. We are preparing two pivotal Phase 3 clinical trials in the treatment of idiopathic sudden sensorineural hearing loss,
or ISSNHL, titled HEALOS and ASSENT. We expect to start enrollment in HEALOS in the fourth quarter of 2015 and in ASSENT in the
first half of 2016. In addition, we are preparing a Phase 2 trial titled REACH in order to test AM-111 in the treatment of cochlear
implant surgery-induced hearing loss. We intend to seek grant funding for REACH and expect to start enrollment in the third quarter
of 2016. We anticipate that our research and development expenses will increase substantially in connection with commencement of
these clinical trials.
|
| · | Other development programs. Other research and development expenses mainly relate to our pre-clinical studies with AM-102 and
AM-123, including costs for production of the pre-clinical compounds and costs paid to academic research institutions in conjunction
with pre-clinical testing. |
For a discussion of our other key financial statement line items,
please see “Item 5—Operating and Financial Review and Prospects–Operating results—Financial Operations
Overview” in the Annual Report.
Results of Operations
The numbers below have been derived from our unaudited condensed
consolidated interim financial statements as of and for the three and nine month periods ended September 30, 2015 and 2014. The
discussion below should be read along with this financial information, and it is qualified in its entirety by reference to them.
Comparison of three months ended September 30, 2015 and 2014
|
Three months ended September 30, |
|
2015 |
|
2014 |
|
Change |
|
(in thousands of CHF) |
|
% |
Research and development |
(5,884) |
|
(4,686) |
|
26% |
General and administrative |
(1,327) |
|
(998) |
|
33% |
Operating loss |
(7,211) |
|
(5,684) |
|
27% |
Finance income/(expense), net |
2,000 |
|
2,323 |
|
(14)% |
Net loss before tax and attributable to owners of the Company |
(5,211) |
|
(3,361) |
|
55% |
Research and development expense
|
Three months ended September 30, |
|
2015 |
|
2014 |
|
Change |
|
(in thousands of CHF) |
|
% |
Clinical projects |
(4,292) |
|
(3,396) |
|
26% |
Pre-clinical projects |
(84) |
|
(15) |
|
458% |
Drug manufacturing and substance |
(570) |
|
(571) |
|
0% |
Employee benefits |
(538) |
|
(412) |
|
31% |
Other research and development expenses |
(401) |
|
(292) |
|
37% |
Total |
(5,884) |
|
(4,686) |
|
26% |
Research and development expense increased 26% from CHF 4.7 million
in the three months ended September 30, 2014 to CHF 5.9 million in the three months ended September 30, 2015. The variance in
expense between the three months ended September 30, 2015 and the corresponding period in 2014 is mainly due to the following:
| · | Clinical projects. In the three months ended September 30, 2015 we incurred higher clinical expenses than in
the three months ended September 30, 2014, primarily due to higher service and milestone costs charged by contracted service providers
in connection with the late stage AM-101 clinical trials, reflecting a higher number of enrolled patients when compared with the
previous reporting period and trial progress. We also incurred higher costs as a result of payments for the initiation of our AM-111
Phase 3 HEALOS trial. |
| · | Pre-clinical projects. In the three months ended September 30, 2015, pre-clinical expenses increased primarily due to
expenses related to our AM-102 pre-clinical project. |
| · | Drug manufacture and substance. In the three months ended September 30, 2015, we incurred generally the same amount
of costs as in the three months ended September 30, 2014. Such costs typically depend on the timing of raw material purchases and
the manufacture of clinical trial supplies. |
| · | Employee benefits. Employee expenses were higher in the three months ended September 30, 2015 than in the same period
2014 due to a higher headcount. |
General and administrative expense
General and administrative expense was CHF 1.3 million in the three
months ended September 30, 2015 compared to CHF 1.0 million in the three months ended September 30, 2014, as a result of higher
administration costs (CHF 0.8 million vs 0.5 million).
We expect that general and administrative expense will increase
in the future as our business expands and we continue to incur costs associated with operating as a public company and protecting
our intellectual property portfolio.
Finance income/ expense net
Net finance income/expense decreased from CHF 2.3 million in the
three months ended September 30, 2014 to CHF 2.0 million in the three month ended September 30, 2015 due to lower unrealized foreign
currency exhange gains (CHF 2.1 million gain vs CHF 2.3 million gain) and higher realized foreign exchange losses (CHF 0.06 million
loss vs CHF 0.03 million gain) in the three months to September 2015.
Comparison of nine months ended September 30, 2015 and 2014
|
Nine months ended September 30, |
|
2015 |
|
2014 |
|
Change |
|
(in thousands of CHF) |
|
% |
Research and development |
(20,865) |
|
(13,036) |
|
60% |
General and administrative |
(3,237) |
|
(3,552) |
|
(9)% |
Operating loss |
(24,102) |
|
(16,588) |
|
45% |
Finance income/(expense), net |
(120) |
|
2,376 |
|
(105)% |
Net loss before tax and attributable to |
|
|
|
|
|
owners of the Company |
(24,221) |
|
(14,212) |
|
70% |
Research and development expense |
|
|
|
|
|
|
|
Nine months ended September 30, |
|
2015 |
|
2014 |
|
Change |
|
(in thousands of CHF) |
|
% |
Clinical projects |
(17,232) |
|
(8,558) |
|
101% |
Pre-clinical projects |
(333) |
|
(1,166) |
|
(71)% |
Drug manufacturing and substance |
(1,058) |
|
(1,355) |
|
(22)% |
Employee benefits |
(1,434) |
|
(1,210) |
|
18% |
Other research and development expenses |
(808) |
|
(747) |
|
8% |
Total |
(20,865) |
|
(13,036) |
|
60% |
Research and development expense increased 60% from CHF 13.0 million
in the nine months ended September 30, 2014 to CHF 20.9 million in the nine months ended September 30, 2015. The variances in expense
between the nine months ended September 30, 2015 and the corresponding period in 2014 are mainly due to the following:
| · | Clinical projects. In the nine months ended September 30, 2015 we incurred significantly higher clinical expenses
than in the nine months ended September 30, 2014, primarily due to higher service and milestone costs charged by contracted service
providers in connection with the late stage AM-101 clinical trials, reflecting higher patient enrollment rates when compared with
the previous reporting period and trial progress. We also incurred higher costs as a result of payments for the initiation of our
AM-111 Phase 3 HEALOS trial. |
| · | Pre-clinical projects. In the nine months ended September 30, 2015, pre-clinical expenses decreased primarily due to
fewer ongoing pre-clinical studies. |
| · | Drug manufacture and substance. In the nine months ended September 30, 2015, we incurred lower costs primarily due to
fluctuations in the timing of raw material purchases and the manufacture of clinical trial supplies. |
| · | Employee benefits. Employee expenses increased in the nine months ended September 30, 2015 compared to the same period
in 2014 due to an increase in headcount. |
General and administrative expense
General and administrative expense decreased 9% from CHF 3.6 million
in the nine months ended September 30, 2014 to CHF 3.2 million in the nine months ended September 30, 2015. While employee costs
increased over the previous reporting period, administration expenses decreased from CHF 2.4 million to CHF 1.8 million as substantial
costs incurred in connection with preparations for our initial public offering (legal and auditing expenses) were expensed in the
nine months ended September 30, 2014.
We expect that general and administrative expense will increase
in the future as our business expands and we continue to incur costs associated with operating as a public company and protecting
our intellectual property portfolio.
Finance income/expense net
Net finance income/expense decreased from an income of CHF 2.4 million
in the nine months ended September 30, 2014 to an expense of CHF 0.1 million in the nine months ended September 30, 2015 due to
substantially higher unrealized foreign currency exchange gains (CHF 2.4 million gain vs CHF 0.2 million loss ) partially offset
by a non-cash interest charge (CHF 0.05 million) for our convertible bond in the nine months to September 2014.
Cash flow
Comparison of nine months ended September 30, 2015 and 2014
The table below summarizes our consolidated statement of cash flows
for the nine months ended September 30, 2015 and 2014:
|
Nine months ended September 30, |
2015 |
|
2014 |
|
(in thousands of CHF) |
Cash used in operating activities |
(22,222) |
|
(14,363) |
Net cash used in investing activities |
(57) |
|
(67) |
Net cash from financing activities |
20,897 |
|
50,065 |
Net effect of currency translation on cash |
(151) |
|
2,392 |
Cash and cash equivalents at beginning of the period |
56,934 |
|
23,866 |
Cash and cash equivalents at end of the period |
55,401 |
|
61,893 |
The increase in cash used in operating activities from CHF 14.4
million in the nine months ended September 30, 2014 to CHF 22.2 million in the nine months ended September 30, 2015, was mainly
due to higher research and development expenses and a decrease in net working capital (higher accrued expenses more than offset
a decrease in payables).
Net cash used in investing activities decreased in the nine months
ended September 30, 2015 due to lower expenditures for purchases of equipment and lower interest income.
Net cash from financing activities of CHF 20.9 million in the nine
months ended September 30, 2015 represents proceeds from our public offering of 5,275,000 common shares at a price of US$4.75 per
share. These proceeds were partially offset by issuance costs associated with the offering. In the nine months ended September
30, 2014 net cash from financing activities was CHF 50.0 million reflecting the net effect of proceeds from our initial public
offering in August 2014.
Cash and funding sources
As of September 30, 2015, we had no long term debt and had no ongoing
material financial commitments, such as lines of credit or guarantees that are expected to affect our liquidity over the next five
years, other than leases.
Funding requirements
We believe that after the closing of our public offering on May 20,
2015, our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements
at least until fall 2017. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources
sooner than we currently expect. Our future funding requirements will depend on many factors, including but not limited to:
| · | the scope, rate of progress, results and cost of our clinical trials, nonclinical testing, and other related activities; |
| · | the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidates and any products
that we may develop; |
| · | the number and characteristics of product candidates that we pursue; |
| · | the cost, timing, and outcomes of regulatory approvals; |
| · | the cost and timing of establishing sales, marketing, and distribution capabilities; and |
| · | the terms and timing of any collaborative, licensing, and other arrangements that we may establish, including any required
milestone and royalty payments thereunder. |
We expect that we will require additional capital to commercialize
our product candidates AM-101 and AM-111. If we receive regulatory approval for AM-101 or AM-111, and if we choose not to grant
any licenses to partners, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing
and distribution, depending on where we choose to commercialize. Additional funds may not be available on a timely basis, on favorable
terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business
strategy. If we are not able to raise capital when needed, we could be forced to delay, reduce or eliminate our product development
programs or commercialization efforts.
We may raise additional capital through the sale of equity or convertible
debt securities. In such an event, your ownership interest will be diluted, and the terms of these new securities may include liquidation
or other preferences that adversely affect your rights as a holder of our common shares.
For more information as to the risks associated with our future funding
needs, see “Item 3—Key Information—Risk factors” in the Annual Report.
Contractual Obligations and Commitments
There have been no material changes to our contractual obligations
outside the ordinary course of our business from those reported in “Item 5—Operating and Financial Review and Prospects—Tabular
disclosure of contractual obligations” in the Annual Report.
Off-Balance Sheet Arrangements
As of the date of this discussion and analysis, we do not have any,
and during the periods presented we did not have any, off-balance sheet arrangements except for the Operating Lease mentioned in
“Item 5—Operating and Financial Review and Prospects—Tabular disclosure of contractual obligations” in
the Annual Report.
Significant Accounting Policies and Use of Estimates and Judgment
There have been no material changes to the significant accounting
policies and estimates described in “Item 5—Operating and Financial Review and Prospects–Operating results—Significant
accounting policies and use of estimates and judgment” in the Annual Report.
Recent Accounting Pronouncements
Except for IFRS 9 which we have not adopted yet, there are no IFRS
standards as issued by the IASB or interpretations issued by the IFRS interpretations committee that are effective for the first
time for the financial year beginning on or after January 1, 2015 that would be expected to have a material impact on our
financial position.
JOBS Act Exemption
On April 5, 2012, the JOBS Act was signed into law. The JOBS
Act contains provisions that, among other things, reduce certain reporting requirements for an “emerging growth company”.
As an emerging growth company, we are not required to provide an auditor attestation report on our system of internal controls
over financial reporting. This exemption will apply for a period of five years following the completion of our initial public offering
(2019) or until we no longer meet the requirements of being an “emerging growth company,” whichever is earlier. We
would cease to be an emerging growth company if we have more than US$1.0 billion in annual revenue, have more than US$700 million
in market value of our common shares held by non-affiliates or issue more than US$1.0 billion of non-convertible debt over a three-year
period.
Cautionary Statement Regarding Forward Looking Statements
Forward-looking statements appear in a number of places in this discussion
and analysis and include, but are not limited to, statements regarding our intent, belief or current expectations. Many of the
forward-looking statements contained in this discussion and analysis can be identified by the use of forward-looking words such
as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,”
“intend,” “estimate” and “potential,” among others. Forward-looking statements are based on
our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements
due to of various factors, including, but not limited to, those identified under the section entitled “Item 3—Key Information—Risk
factors” in the Annual Report. These risks and uncertainties include factors relating to:
| · | our operation as a development stage company with limited operating history and a history of operating losses; |
| · | our need for substantial additional funding before we can expect to become profitable from sales of our products; |
| · | our dependence on the success of AM-101 and AM-111, which are still in clinical development and may eventually prove to be
unsuccessful; |
| · | the chance that we may become exposed to costly and damaging liability claims resulting from the testing of our product candidates
in the clinic or in the commercial stage; |
| · | the chance our clinical trials may not be completed on schedule, or at all, as a result of factors such as delayed enrollment
or the identification of adverse effects; |
| · | uncertainty surrounding whether and when any of our product candidates will receive regulatory approval, which is necessary
before they can be commercialized; |
| · | if our product candidates obtain regulatory approval, our being subject to expensive ongoing obligations and continued regulatory
overview; |
| · | enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval and commercialization; |
| · | the chance that we do not obtain orphan drug exclusivity for AM-111, which would allow our competitors to sell products that
treat the same conditions; |
| · | dependence on governmental authorities and health insurers establishing adequate reimbursement levels and pricing policies; |
| · | our products may not gain market acceptance, in which case we may not be able to generate product revenues; |
| · | our reliance on our current strategic relationships with INSERM or Xigen and the potential failure to enter into new strategic
relationships; |
| · | our reliance on third parties to conduct our nonclinical and clinical trials and on third-party single-source suppliers to
supply or produce our product candidates; and |
| · | other risk factors discussed under “Item 3—Key Information—Risk factors” included in the Annual Report. |
Forward-looking statements speak only as of the date
they are made, and we do not undertake any obligation to update them in light of new information or future developments or to release
publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated
events.
Exhibit 99.3
Auris Medical News Release
Auris Medical Holding AG Reports Third Quarter 2015 Financial
Results and Provides Business Update
Zug, Switzerland, November 12, 2015 – Auris Medical Holding
AG (NASDAQ: EARS) today provided an update on the Company’s business and announced financial results for the third quarter
ended September 30, 2015.
"Auris Medical continued to make good progress in the third
quarter of 2015," commented Thomas Meyer, the Company’s founder, Chairman and CEO. "Preparations for the three
clinical trials in our AM-111 hearing loss program advanced well, with the first study expected to begin patient recruitment shortly.
Importantly, our hearing loss program is generating considerable interest within the ENT community. At the same time, we reinforced
our leadership in tinnitus research by taking our project AM-102 into the next stage of drug discovery. After several years of
collaborative efforts together with our partners, we are very excited about AM-102’s potential of becoming a powerful second
generation tinnitus treatment.”
Third Quarter and Recent Business Highlights
· | | Progressed with enrolment into pivotal AM-101 trials. The Phase 3 clinical program
with AM-101 in acute inner ear tinnitus continued to progress. The Company expects to have first top-line Phase 3 clinical data
for AM-101 in the second quarter of 2016. |
· | | Launched HEALOS Phase 3 trial. In HEALOS, the first of two pivotal trials with AM-111
in the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL; a.k.a. “sudden deafness”), the first study
sites in Europe and Asia were opened, and enrolment is expected to begin shortly. HEALOS will enroll 255 patients suffering from
acute severe to profound hearing loss within 72 hours from ISSNHL onset. They will be randomized to receive a single intratympanic
dose of either AM-111 at 0.4 mg/mL or 0.8 mg/mL or placebo, and will be followed for three months. The primary efficacy endpoint
is the improvement of pure tone hearing threshold from baseline to day 28 at the average of the three most affected contiguous
test frequencies. |
· | | Advanced preparations for ASSENT and REACH trials. Preparations for the two other
planned AM-111 trials progressed further. For ASSENT, the second pivotal trial with AM-111 in ISSNHL, the design of the study
protocol was completed, subject to final consultation with the FDA. The trial will be conducted primarily in North America, and
is expected to begin enrolling patients in the first half of 2016. For REACH, a Phase 2 proof of concept study to assess AM-111’s
otoprotective effects in cochlear implant surgery induced hearing loss, the study protocol was finalized based on additional FDA
feedback. Contingent on securing grant funding, the trial could be initiated in the third quarter of 2016. |
· | | Provided medical education on acute hearing loss. In September 2015, Auris Medical
organized a corporate symposium, “Rational Pharmacotherapy for Acute Hearing Loss – Recent Advances and Perspectives”,
at the Annual Meeting of the American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS) in Dallas, TX. The symposium
featured presentations from leading experts on hearing preservation following acute cochlear stress injury, inner ear drug delivery
and the state of clinical research in acute hearing loss. The event highlighted the significant unmet medical need in the treatment
of acute hearing loss, and laid out key considerations for the design of clinical trials. A Webcast of the event is available
on Auris Medical’s website in the “Events” section. |
· | | Expanded research collaboration with King’s College London. Auris Medical initiated
a drug discovery collaboration with the Institute of Pharmaceutical Science of King’s College London, which expands on earlier
work by the Wolfson Centre for Age-Related Diseases at King’s. Under the collaboration, King’s will develop and optimize
a range of specific small molecules for Auris Medical’s AM-102 project. The AM-102 compounds bind to a novel, undisclosed
drug target that is different from AM-101’s target, and has been previously validated in collaboration with another research
institution. From the AM-102 research project, Auris Medical aims to select a lead compound for further preclinical and subsequent
clinical development as a second generation tinnitus treatment. |
Financial Results
As of September 30, 2015, the Company had CHF 55.4 million in cash
and cash equivalents. Operating expenses for the three months ended September 30, 2015 were CHF 7.2 million, with CHF 5.9 million
attributable to research and development. This compares to operating expenses of CHF 5.7 million and research and development expenses
of CHF 4.7 million for the same period in 2014. The Company reported a net loss for the quarter ended September 30, 2015 of CHF
5.2 million, or CHF 0.15 per share. This compares to a net loss of CHF 3.4 million, or CHF 0.14 per share, for the same period
in 2014.
For the nine month period ended September 30, 2015, operating expenses
were CHF 24.1 million, with CHF 20.9 million attributable to research and development. This compares to operating expenses of CHF
16.6 million and research and development expenses of CHF 13.0 million for the same period in 2014. The Company reported a net
loss for the nine months ended September 30, 2015 of CHF 24.2 million, or CHF 0.76 per share. This compares to a net loss of CHF
14.2 million, or CHF 0.69 per share, for the same period in 2014.
The increases in operating expenses, and resulting increases in
net loss, for the three- and nine-month periods ended September 30, 2015 over the comparable periods in 2014 reflect primarily
the progression of the AM-101 Phase 3 clinical development program and preparations for the late stage AM-111 clinical program.
The Company expects its operating
expenses for the 2015 financial year to be in line with previous guidance of CHF 30.0 to 35.0
million.
Conference Call / Webcast Information
Auris Medical will host a live conference call and webcast to discuss
the Company's financial results and provide a general business update. The call is scheduled for November 12, 2015 at 8:00 a.m.
Eastern Time (2:00 p.m. Central European Time). To participate in this conference call, dial 1 855 217 7942 (USA) or +1 646 254
3369 (International), and enter passcode 4621688. A live, listen-only audio webcast of the conference call can be accessed on the
Investor Relations section of the Auris Medical website at: www.aurismedical.com. A replay will be available approximately two
hours following the live call also on the Company’s website.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to
developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the
development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic
injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects.
The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding
AG trade on the NASDAQ Global Market under the symbol "EARS".
Forward-looking Statements
This press release may contain statements that constitute “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating,
financial or business performance or Auris Medical’s strategies or expectations. In some cases, you can identify these statements
by forward-looking words such as “may,” “might,” “will,” “should,” “expects,”
“plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,”
“potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements
are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause
actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks
and uncertainties include, but are not limited to, the timing and conduct of clinical trials of Auris Medical’s product candidates,
the clinical utility of Auris Medical’s product candidates, the timing or likelihood of regulatory filings and approvals,
Auris Medical’s intellectual property position and Auris Medical’s financial position, including the impact of any
future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical’s capital structure, including
future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption
“Risk Factors” in Auris Medical’s Annual Report on Form 20-F, the prospectus dated May 14, 2015 relating to its
Registration Statement on Form F-1 and future filings with the Securities and Exchange Commission. Forward-looking statements speak
only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information,
future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified
in their entirety by this cautionary statement.
Company: Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94, ear@aurismedical.com
Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685, matthew@lifesciadvisors.com
Auris Medical Holding AG
Condensed Consolidated Interim Statement of Profit or Loss and Other
Comprehensive Income (unaudited)
(in CHF thousands, except share and currency data)
| |
Three Months Ended September 30, | |
Nine Months Ended September 30, |
| |
2015 | |
2014 | |
2015 | |
2014 |
Research and development expenses | |
| (5,884 | ) | |
| (4,686 | ) | |
| (20,865 | ) | |
| (13,036 | ) |
General and administrative expenses | |
| (1,327 | ) | |
| (998 | ) | |
| (3,237 | ) | |
| (3,552 | ) |
Operating loss | |
| (7,211 | ) | |
| (5,684 | ) | |
| (24,102 | ) | |
| (16,588 | ) |
Finance income/(expense), net | |
| 2,000 | | |
| 2,323 | | |
| (120 | ) | |
| 2,376 | |
Loss before tax | |
| (5,211 | ) | |
| (3,361 | ) | |
| (24,221 | ) | |
| (14,212 | ) |
Net loss attributable to owners of the Company | |
| (5,211 | ) | |
| (3,361 | ) | |
| (24,221 | ) | |
| (14,212 | ) |
Other comprehensive income: | |
| | | |
| | | |
| | | |
| | |
Items that will never be reclassified to profit or loss: | |
| | | |
| | | |
| | | |
| | |
Remeasurements of defined benefits liability | |
| (4 | ) | |
| 112 | | |
| (233 | ) | |
| (312 | ) |
Items that are or may reclassified to profit or loss: | |
| | | |
| | | |
| | | |
| | |
Foreign currency translation differences | |
| (41 | ) | |
| (74 | ) | |
| 16 | | |
| (71 | ) |
Other comprehensive income | |
| (44 | ) | |
| 37 | | |
| (217 | ) | |
| (384 | ) |
Total comprehensive loss attributable to owners of the Company | |
| (5,255 | ) | |
| (3,323 | ) | |
| (24,438 | ) | |
| (14,596 | ) |
Loss per share, basic and diluted | |
| (0.15 | ) | |
| (0.14 | ) | |
| (0.76 | ) | |
| (0.69 | ) |
Weighted average common shares outstanding, basic and diluted | |
| 34,290,141 | | |
| 24,589,852 | | |
| 31,828,984 | | |
| 20,488,392 | |
Currency rate CHF / USD | |
| 0.9525 | | |
| 0.9134 | | |
| 0.9507 | | |
| 0.8960 | |
Auris Medical Holding AG
Condensed Consolidated Interim Statement of Financial Position (unaudited)
(in CHF thousands)
| |
September 30,
2015 | |
December 31,
2014 |
Assets | |
| | | |
| | |
Non-current assets | |
| | | |
| | |
Property and equipment | |
| 247 | | |
| 235 | |
Intangible assets | |
| 1,483 | | |
| 1,483 | |
Deferred tax asset | |
| - | | |
| 33 | |
Total non-current assets | |
| 1,730 | | |
| 1,751 | |
Current assets | |
| | | |
| | |
Current financial assets and other receivables | |
| 576 | | |
| 543 | |
Prepayments | |
| 294 | | |
| 265 | |
Cash and cash equivalents | |
| 55,401 | | |
| 56,934 | |
Total current assets | |
| 56,271 | | |
| 57,742 | |
Total assets | |
| 58,001 | | |
| 59,493 | |
Equity and Liabilities | |
| | | |
| | |
Equity | |
| | | |
| | |
Share capital | |
| 13,718 | | |
| 11,604 | |
Share premium | |
| 112,645 | | |
| 93,861 | |
Foreign currency translation reserve | |
| (35 | ) | |
| (51 | ) |
Accumulated deficit | |
| (76,379 | ) | |
| (52,131 | ) |
Total shareholders’ equity attributable to owners of the Company | |
| 49,949 | | |
| 53,283 | |
Non-current liabilities | |
| | | |
| | |
Employee benefits | |
| 1,759 | | |
| 1,411 | |
Deferred tax liabilities | |
| 328 | | |
| 360 | |
Total non-current liabilities | |
| 2,086 | | |
| 1,771 | |
Current liabilities | |
| | | |
| | |
Trade and other payables | |
| 2,822 | | |
| 3,234 | |
Accrued expenses | |
| 3,143 | | |
| 1,205 | |
Total current liabilities | |
| 5,965 | | |
| 4,439 | |
Total liabilities | |
| 8,052 | | |
| 6,210 | |
Total equity and liabilities | |
| 58,001 | | |
| 59,493 | |
Currency rate CHF / USD | |
| 0.9739 | | |
| 0.8841 | |
Auris Medical Holding AG
Condensed Consolidated Interim Statement of Profit or Loss and Other
Comprehensive Income (unaudited)
(convenience presentation in USD thousands, except share data)
| |
Three Months Ended September 30, | |
Nine Months Ended September 30, |
| |
2015 | |
2014 | |
2015 | |
2014 |
Research and development expenses | |
| (6,042 | ) | |
| (4,812 | ) | |
| (21,424 | ) | |
| (13,386 | ) |
General and administrative expenses | |
| (1,362 | ) | |
| (1,024 | ) | |
| (3,324 | ) | |
| (3,647 | ) |
Operating loss | |
| (7,404 | ) | |
| (5,837 | ) | |
| (24,748 | ) | |
| (17,033 | ) |
Finance income/(expense), net | |
| 2,054 | | |
| 2,386 | | |
| (123 | ) | |
| 2,440 | |
Loss before tax | |
| (5,351 | ) | |
| (3,451 | ) | |
| (24,871 | ) | |
| (14,593 | ) |
Net loss attributable to owners of the Company | |
| (5,351 | ) | |
| (3,451 | ) | |
| (24,871 | ) | |
| (14,593 | ) |
Other comprehensive income: | |
| | | |
| | | |
| | | |
| | |
Items that will never be reclassified to profit or loss: | |
| | | |
| | | |
| | | |
| | |
Remeasurements of defined benefits liability | |
| (4 | ) | |
| 115 | | |
| (239 | ) | |
| (321 | ) |
Items that are or may reclassified to profit or loss: | |
| | | |
| | | |
| | | |
| | |
Foreign currency translation differences | |
| (42 | ) | |
| (76 | ) | |
| 17 | | |
| (73 | ) |
Other comprehensive income | |
| (46 | ) | |
| 38 | | |
| (222 | ) | |
| (394 | ) |
Total comprehensive loss attributable to owners of the Company | |
| (5,396 | ) | |
| (3,412 | ) | |
| (25,093 | ) | |
| (14,987 | ) |
Loss per share, basic and diluted | |
| (0.16 | ) | |
| (0.14 | ) | |
| (0.78 | ) | |
| (0.71 | ) |
Weighted average common shares outstanding, basic and diluted | |
| 34,290,141 | | |
| 24,589,852 | | |
| 31,828,984 | | |
| 20,488,392 | |
Solely for the convenience of the reader, unless otherwise indicated,
all Swiss Franc amounts stated in the Condensed Consolidated Statement of Profit and Loss for the 3 and 9 months ended September
30, 2015 and September 30, 2014, have been translated into U.S. dollars at the rate on September 30, 2015 of USD 1.0268 / CHF 1.00.
These translations should not be considered representations that any such amounts have been, could have been or could be converted
into U.S. dollars at that or any other exchange rate as at that or any other date.
Auris Medical Holding AG
Condensed Consolidated Interim Statement of Financial Position (unaudited)
(convenience presentation in USD thousands)
| |
September 30,
2015 | |
December 31,
2014 |
Assets | |
| | | |
| | |
Non-current assets | |
| | | |
| | |
Property and equipment | |
| 254 | | |
| 242 | |
Intangible assets | |
| 1,522 | | |
| 1,522 | |
Deferred tax asset | |
| - | | |
| 34 | |
Total non-current assets | |
| 1,776 | | |
| 1,798 | |
Current assets | |
| - | | |
| | |
Current financial assets and other receivables | |
| 591 | | |
| 557 | |
Prepayments | |
| 302 | | |
| 272 | |
Cash and cash equivalents | |
| 56,885 | | |
| 58,460 | |
Total current assets | |
| 57,779 | | |
| 59,289 | |
Total assets | |
| 59,555 | | |
| 61,087 | |
Equity and Liabilities | |
| - | | |
| | |
Equity | |
| - | | |
| | |
Share capital | |
| 14,085 | | |
| 11,915 | |
Share premium | |
| 115,664 | | |
| 96,377 | |
Foreign currency translation reserve | |
| (36 | ) | |
| (52 | ) |
Accumulated deficit | |
| (78,425 | ) | |
| (53,529 | ) |
Total shareholders’ equity attributable to owners of the Company | |
| 51,288 | | |
| 54,711 | |
Non-current liabilities | |
| - | | |
| | |
Employee benefits | |
| 1,806 | | |
| 1,448 | |
Deferred tax liabilities | |
| 336 | | |
| 370 | |
Total non-current liabilities | |
| 2,142 | | |
| 1,818 | |
Current liabilities | |
| - | | |
| | |
Trade and other payables | |
| 2,898 | | |
| 3,321 | |
Accrued expenses | |
| 3,227 | | |
| 1,237 | |
Total current liabilities | |
| 6,125 | | |
| 4,558 | |
Total liabilities | |
| 8,267 | | |
| 6,376 | |
Total equity and liabilities | |
| 59,555 | | |
| 61,087 | |
Solely for the convenience of the reader, unless otherwise indicated,
all Swiss Franc amounts stated in the Condensed Consolidated Statement of Financial Position as at September 30, 2015 and December
31, 2014, have been translated into U.S. dollars at the rate on September 30, 2015 of USD 1.0268 / CHF 1.00. These translations
should not be considered representations that any such amounts have been, could have been or could be converted into U.S. dollars
at that or any other exchange rate as at that or any other date.
Page 7 of 7
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Oct 2023 to Oct 2024